Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413538 | 0.92 | CRBN (0.57) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL1413390 | 0.88 | CRBN (0.59) | CRBNCSNK1A1IKZF2GSPT1IKZF1 | |
| SCHEMBL1413409 | 0.86 | CRBN (0.63) | CRBNCSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413525 | 0.86 | CRBN (0.57) | CRBNCSNK1A1IKZF2GSPT1IKZF1 | |
| SCHEMBL1413715 | 0.85 | CRBN (0.62) | CRBNCSNK1A1DDB1GSPT1CYP2C19 | |
| SCHEMBL1413692 | 0.85 | CRBN (0.62) | CRBNCSNK1A1IKZF2GSPT1IKZF1 | |
| SCHEMBL1413446 | 0.85 | CRBN (0.62) | CRBNCSNK1A1IKZF2GSPT1IKZF1 | |
| SCHEMBL1413746 | 0.84 | CRBN (0.50) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL1413504 | 0.84 | CRBN (0.59) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL1964243 | 0.83 | CRBN (0.53) | CRBNCSNK1A1IKZF2DDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964354-B2 | Use of micro-RNA as a biomarker of immunomodulatory drug activity | CELGENE CORPORATION (US) | 2011-06-21 | — | — | US | claimed |
| EP-2235213-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-10-06 | — | — | EP | claimed |
| WO-2009085234-A9 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-08-12 | — | — | WO | claimed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090176237-A1 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2009-07-09 | — | — | US | claimed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220026439-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV (BE) | 2022-01-27 | — | — | US | disclosed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3077548-B1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORP (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20090232796-A1 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION | 2009-09-17 | — | — | US | disclosed |
| WO-2009105256-A2 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090176237-A1 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2009-07-09 | — | — | US | disclosed |
| WO-2009085262-A1 | METHOD OF TREATING CANCER WITH IMMUNOMODULATORY COMPOUNDS AND IGG | CELGENE CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009075797-A2 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090148853-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885CSNK1A1 322/4885IKZF2 1029/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | CRBN 5/4885CSNK1A1 7/4885IKZF2 26/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | CRBN 401/4885CSNK1A1 2614/4885IKZF2 79/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CSNK1A1 554/4885IKZF2 3972/4885 |
| US-20090232796-A1 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CD40LG, CD40, ICOS | CRBN 1352/4885CSNK1A1 4280/4885IKZF2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.